HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death

Int J Infect Dis. 2009 Nov;13(6):722-9. doi: 10.1016/j.ijid.2008.11.013. Epub 2009 Feb 4.

Abstract

Background: We conducted a prospective, multicenter observational cohort study in Thailand to characterize the epidemiology of extrapulmonary tuberculosis (TB) in HIV-infected persons and to identify risk factors for death.

Methods: From May 2005 to September 2006, we enrolled, interviewed, examined, and performed laboratory tests on HIV-infected adult TB patients and followed them from TB treatment initiation until the end of TB treatment. We conducted multivariate proportional hazards analysis to identify factors associated with death.

Results: Of the 769 patients, pulmonary TB only was diagnosed in 461 (60%), both pulmonary and extrapulmonary TB in 78 (10%), extrapulmonary TB at one site in 223 (29%), and extrapulmonary TB at more than one site in seven (1%) patients. Death during TB treatment occurred in 59 of 308 patients (19%) with any extrapulmonary involvement. In a proportional hazards model, patients with extrapulmonary TB had an increased risk of death if they had meningitis, and a CD4+ T-lymphocyte count <200 cells/microl. Patients who received co-trimoxazole, fluconazole, and antiretroviral therapy during TB treatment had a lower risk of death.

Conclusions: Among HIV-infected patients with TB, extrapulmonary disease occurred in 40% of the patients, particularly in those with advanced immune suppression. Death during TB treatment was common, but the risk of death was reduced in patients who took co-trimoxazole, fluconazole, and antiretroviral therapy.

Publication types

  • Multicenter Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS-Related Opportunistic Infections / complications
  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / mortality*
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use
  • Cohort Studies
  • Female
  • Fluconazole / therapeutic use
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / mortality*
  • Humans
  • Male
  • Risk Factors
  • Survival Analysis
  • Survival Rate
  • Thailand / epidemiology
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Tuberculosis / complications
  • Tuberculosis / drug therapy
  • Tuberculosis / microbiology
  • Tuberculosis / mortality*
  • Tuberculosis, Pulmonary / complications
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / mortality*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Anti-Infective Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Fluconazole